Anaconda BioMed raises €49M to bring stroke catheters to the US

What's the deal? Anaconda BioMed, a Catalan medical-device maker, has raised €49 million ($56 million) in a late-stage round led by US-based Omega FundsDealroom has a profile for this one. Try Dealroom →, an existing backer. COFIDESDealroom has a profile for this one. Try Dealroom → joined through its co-investment fund, alongside returning investors Asabys PartnersDealroom has a profile for this one. Try Dealroom →, Ysios CapitalDealroom has a profile for this one. Try Dealroom →, and the CDTIDealroom has a profile for this one. Try Dealroom →.

What's the endgame? The company builds trombectomy catheters — devices threaded into blood vessels to remove clots. Its funnel-shaped Funnel Catheter platform is designed to capture the clot, cut embolic complications, and maximise brain reperfusion, aiming to reduce disability and death from stroke.

Where the money goes: Proceeds will fund product development and clinical work, chiefly finishing a US pivotal study evaluating the safety of its ANA Funnel Catheter.

Why now? Chief executive officer Trent Reutiman said the company aims to complete clinical activity in 2027 and reach the US market in the first half of 2028. In Europe, its ANA5 device already holds CE marking, with commercialisation planned for the second half of 2027.

Founded in 2015 by Marc Ribó and Ofir Arad as a spin-off from Barcelona's Vall d'Hebron Research Institute, Anaconda BioMed has raised close to $100 million to date. It manufactures at a plant in Sant Quirze del Vallès and employs about 30 people in Catalonia, plus roughly eight in the US.

The signal: The round ranks around the 91st percentile among all-time late-stage venture deals in Spanish health, a sign of investor appetite for medtech with a clear regulatory path and a US market in sight.

Read more: capital-riesgo.es

Image credit: Generated with Gemini